SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...
Approval for the technology, which integrates with a smartphone, came sooner than company officials expected. A fully mobile continuous glucose monitoring (CGM) system, which features wireless ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) the leader in continuous glucose monitoring (CGM) for people with diabetes, is pleased to announce the Food and Drug Administration (FDA) ...
Share price of DexCom, Inc.DXCM jumped 4.8% on Aug 25, following the FDA approval of the DexCom G5 Mobile Continuous Glucose Monitoring (CGM) System. The fully portable product is the first and ...
For the first time, the US Food and Drug Administration has approved the use of a continuous glucose monitoring (CGM) system to replace finger-stick testing for determining insulin doses. The decision ...
The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...
A new diabetes device may make tracking blood sugars and taking medication easier. The U.S. Food and Drug Administration said Tuesday that the Dexcom G5 continuous glucose monitoring system (CGM) can ...
The markets seem to be happy with South San Francisco, CA-based DexCom, Inc. DXCM. The company’s stock price rallied 4.8% to close at $82.62 yesterday following its announcement, that the Centers for ...
It’s a pretty good day for San Diego-based Dexcom. The company announced that it won CE Mark approval for its G5 continuous glucose monitor in the European Union. This means the device will be ...
The Centers for Medicare and Medicaid Services has released guidelines on Medicare coverage for continuous glucose monitors, and one medtech company stands to make a whole lot of money from the change ...
The Food and Drug Administration (FDA) has expanded the use of Dexcom's G5 Mobile Continuous Glucose Monitoring (CGM) System to allow for replacement of blood glucose testing for diabetes treatment ...
As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback